据证券之星公开数据整理，近期澳洋健康（002172）发布2025年中报。截至本报告期末，公司营业总收 入9.03亿元，同比下降12.49%，归母净利润3155.59万元，同比下降15.46%。按单季度数据看，第二季 度营业总收入4.51亿元，同比上升0.15%，第二季度归母净利润1305.67万元，同比上升98.17%。本报告 期澳洋健康短期债务压力上升，流动比率达0.64。 合同负债变动幅度为32.95%,原因:本期末预收医疗服务相关款项增加。 财务费用变动幅度为212.07%,原因:本期用于担保的定期存款到期减少，相应利息收入减少。 经营活动产生的现金流量净额变动幅度为78.25%,原因:本期以现金收付货款净额增加。 本次财报公布的各项数据指标表现一般。其中，毛利率14.85%，同比增10.09%，净利率3.54%，同比减 3.94%，销售费用、管理费用、财务费用总计8025.45万元，三费占营收比8.89%，同比增4.36%，每股净 资产0.22元，同比增26.58%，每股经营性现金流-0.07元，同比增78.25%，每股收益0.04元，同比减 20.0% 财务报表中对有大幅变动的财务项目的原因说明如下 ...

江苏澳洋健康产业股份有限公司 2025 年半年度财务报告 江苏澳洋健康产业股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 江苏澳洋健康产业股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：江苏澳洋健康产业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 462,388,637.66 | 521,489,938.85 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 39,580,999.85 | 70,540,492.89 | | 应收账款 | 326,531,285.75 | 291,583,598.00 | | 应收款项融资 | 14,214,785.15 | 10,635,414.43 | | 预付款项 | 15,211,8 ...

江苏澳洋健康产业股份有限公司 2025 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性 | | 占用方与上 | 上市公司核 | 年期初占 2025 | 2025 年半年度占用累 | 2025 年半年度占 | 年半年度偿 2025 | 2025 年 6 月 | 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | 用资金余额 | 计发生金额（不含利 | 用资金的利息(如 | 还累计发生金额 | 占用资金余 | 因 | 占用性质 | | | | 联关系 | 目 | | 息） | 有) | | 额 | | | | 控股股东、 | | | | | | | | | | 非经营性占 | | 实际控制 | | | | | | | | | | 用 | | 人及其附 | | | | | | | | | | 非经营性占 | | 属企业 | | | | | | | | | | 用 | | 小计 | - | - | - | | | ...

格隆汇8月26日丨澳洋健康(002172.SZ)公布2025年半年度报告，上半年公司实现营业收入9.03亿元，同 比下降12.49%；归属于上市公司股东的净利润3155.59万元，同比下降15.46%；归属于上市公司股东的 扣除非经常性损益的净利润2967.42万元，同比下降13.71%；基本每股收益0.04元。 ...

江苏澳洋健康产业股份有限公司 2025 年半年度报告全文 江苏澳洋健康产业股份有限公司 2025 年半年度报告 2025 年 8 月 1 江苏澳洋健康产业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人沈学如、主管会计工作负责人李霞及会计机构负责人(会计主 管人员)李霞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划及经营目标等前瞻性陈述，不构成公司对投资 者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异。 公司存在国家政策对医疗健康产业影响等风险，敬请广大投资者注意投资 风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | . | DK | | --- | --- | | 1 | | | 第二节 | 公司简介和主要财务指标 6 | | --- | --- | | 第三节 | ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a decline in revenue and profit, alongside a high PE ratio compared to industry averages [1][2] - As of August 25, Aoyang Health's stock closed at 4.27 yuan, down 2.06%, with a rolling PE ratio of 115.45 times and a total market capitalization of 3.27 billion yuan [1] - The average PE ratio for the healthcare service industry is 50.60 times, with a median of 64.30 times, placing Aoyang Health at the 38th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Aoyang Health reported an operating income of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.49 million yuan, down 39.82% [2] - The company's sales gross margin stands at 15.09% [2] - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a significant decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1][2] - Aoyang Health's closing stock price on August 22 was 4.36 yuan, down 1.80%, with a rolling PE ratio of 117.88 times, and a total market capitalization of 3.339 billion yuan [1] - The average PE ratio for the healthcare service industry is 49.39 times, with a median of 62.33 times, placing Aoyang Health at the 39th position within the industry [1][2] Group 2 - For the first quarter of 2025, Aoyang Health reported an operating income of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% year-on-year, with a sales gross margin of 15.09% [2] - As of March 31, 2025, Aoyang Health had 53,714 shareholders, a decrease of 3,624 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1]

Group 1 - The high-pressure oxygen chamber concept sector experienced a decline of 0.76%, ranking among the top declines in concept sectors as of the market close on August 22 [1] - Within the sector, major declines were observed in companies such as Samsung Medical, Aoyang Health, and Dahu Co., with notable increases in Hangyang Co., Yinkang Life, and International Medicine, which rose by 0.97%, 0.86%, and 0.37% respectively [1] Group 2 - The high-pressure oxygen chamber concept sector saw a net outflow of 260 million yuan in principal funds today, with six stocks experiencing net outflows [2] - The stock with the highest net outflow was Tiedao Heavy Industry, which had a net outflow of 143 million yuan, followed by Innovative Medical, Samsung Medical, and Aoyang Health with net outflows of 60.83 million yuan, 43.65 million yuan, and 13.12 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included International Medicine, Jinling Pharmaceutical, and Yinkang Life, with net inflows of 3.35 million yuan, 3.27 million yuan, and 3.20 million yuan respectively [2]

Group 1 - As of August 21, 2025, Aoyang Health's stock price closed at 4.44 yuan, an increase of 0.16 yuan, representing a rise of 3.74% from the previous trading day [1] - The stock opened at 4.29 yuan, reached a high of 4.55 yuan, and a low of 4.27 yuan, with a trading volume of 829,827 hands and a transaction amount of 368 million yuan [1] - Aoyang Health operates in the healthcare services sector, with business areas including medical health services, pharmaceutical distribution, hair medical services, assisted reproduction, and medical beauty [1] Group 2 - On the morning of August 21, Aoyang Health experienced a rapid pullback, with a drop of over 2% within five minutes, reaching a low of 4.4 yuan and a transaction amount of 65.59 million yuan [1] - In terms of capital flow, on August 21, the net inflow of main funds was 23.03 million yuan, with a cumulative net inflow of 24.78 million yuan over the past five trading days [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a significant decline in revenue and profit in the first quarter of 2025 compared to the previous year [1][2] - Aoyang Health's stock closed at 4.44 yuan, with a PE ratio of 120.04, marking a new low in 48 days, and a total market capitalization of 3.4 billion yuan [1] - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with its main products being medical services and pharmaceutical logistics [1] Group 2 - In the first quarter of 2025, Aoyang Health reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.49 million yuan, down 39.82% [2] - The average PE ratio for the medical services industry is 49.07, with a median of 65.74, positioning Aoyang Health at 39th place within the industry [1][2] - The company has received various honors, including being ranked 32nd in the non-public hospital top 100 list and second among county-level non-public hospitals in China [1]